A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

Table 2 Results for the adherent group and for the combined adherent and non-adherent groups (intent-to treat analysis, ITT) *

	Adherent group (n = 271)			Adherent and non-adherent groups combined (n = 516)
Hospitalization parameter	OLZ (n = 159)	RIS (n = 112)	P-value	OLZ (n = 297)	RIS (n = 219)	P-value
% Patients hospitalized
Unadjusted	14.5%	24.1%	0.044†	23.6%	31.5%	0.045†
Adjusted	2.0%	9.8%	0.040^‡	7.6%	20.7%	0.085^‡
Days hospitalized
Days, Average Unadjusted	9.9	14.5	0.425	19.1	17.6	0.755
Log Days, Unadjusted	0.59	0.94	0.070^§	0.73	0.99	0.039^§
Log Days, Adjusted	1.24	1.61	0.035\|\|	1.30	1.48	0.139\|\|
Days, 2-Part Estimate, Adj.	7.3	19.0	--	15.9	21.0	--
Time to first hospitalization
Mean	176.1	111.0	0.107#	156.4	167.8	0.476#
Median	173	94	--	153	146	--

* Time to hospitalization: Number of days to first hospitalization for outpatients following initiation of the index drug; Number of days to first re-hospitalization post discharge from index hospitalization for participants who were inpatients at the time of initiation on index drug Adjusted: Controlling for gender, age at illness onset, race, age at baseline, prior use (60 days pre-initiation) of oral antipsychotics, mood stabilizers, antipsychotics in depot formulation (Y/N). † Mantel-Haenszel test ^‡Logistic Regression test ^§ t-test for the log transformation of hospital stay + 1 || GLM for log transformation test # Log Rank test of the Kaplan – Meier survival analysis

ISSN: 1744-859X